Insider activity at Athira Pharma, Inc. has been all selling for a year now: about $43,000 from five sellers, and zero buyers in open-market trades.
Selling on its own is common and often pre-planned (10b5-1 plans, taxes, diversification), so it matters more when it is unusually heavy or broad.
No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | San Martin Javier | Executive Officer | Sell | 1,644 | $6.88 | $11K | SEC |
| Jan 5, 2026 | Litton Mark James | CEO | Sell | 2,586 | $6.88 | $18K | SEC |
| Jan 5, 2026 | Renninger Robert | CFO | Sell | 297 | $6.88 | $2K | SEC |
| Jan 5, 2026 | CHURCH KEVIN | Executive Officer | Sell | 876 | $6.88 | $6K | SEC |
| Jan 5, 2026 | Worthington Mark | Executive Officer | Sell | 876 | $6.88 | $6K | SEC |
| Jul 2, 2025 | CHURCH KEVIN | Executive Officer | Sell | 8,526 | $0.29 | $2K | SEC |
| Jul 2, 2025 | Litton Mark James | CEO | Sell | 25,123 | $0.29 | $7K | SEC |
| Jul 2, 2025 | San Martin Javier | Executive Officer | Sell | 10,842 | $0.29 | $3K | SEC |
| Jul 2, 2025 | Worthington Mark | Executive Officer | Sell | 8,526 | $0.29 | $2K | SEC |
| Jul 2, 2025 | Renninger Robert | Executive Officer | Sell | 2,897 | $0.29 | $840 | SEC |
| Jan 3, 2025 | San Martin Javier | Executive Officer | Sell | 10,826 | $0.56 | $6K | SEC |
| Jan 3, 2025 | Litton Mark James | CEO | Sell | 25,107 | $0.56 | $14K | SEC |
| Jan 3, 2025 | CHURCH KEVIN | Executive Officer | Sell | 8,510 | $0.56 | $5K | SEC |
| Jan 3, 2025 | Renninger Robert | Officer | Sell | 2,881 | $0.56 | $2K | SEC |
| Jan 3, 2025 | Worthington Mark | Executive Officer | Sell | 8,510 | $0.56 | $5K | SEC |
In the last 12 months Athira Pharma, Inc. insiders made open-market purchases worth about $0 and sales worth about $43,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in ATHA was filed on 2026-01-05.
No congressional trades in ATHA were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).